In support of the former, our analysis of publicly available RNA-seq data corresponding to pre-treatment tumor tissues collected from patients who received CTLA-4 inhibitor suggests that lack of a B cell response is a predictor of poor response to immune checkpoint inhibitors. Here, CTLA4 is linked to neoplasm.